[ad_1]
A potential HIV vaccine developed by Johnson & Johnson failed to provide protection against the virus in a mid-term study, the drugmaker said on Tuesday.
plans to end this study, which involved young women from sub-Saharan Africa. But researchers will pursue a separate, late-stage trial involving a different composition of the vaccine in men and transgender people.
The study in sub-Saharan Africa looked at approximately 2,600 women considered to be at high risk of contracting HIV, which causes AIDS. Participants were randomly selected to receive either the vaccine or a placebo, and the researchers found that the vaccine was only 25% effective in preventing HIV.
“HIV is a unique and complex virus that has long posed unprecedented challenges for vaccine development due to its ability to attack, deflect and evade the human immune system,” said J&J Scientific Director Dr Paul Stoffels in a statement.
J&J said his other study on the potential vaccine was being conducted in Europe and the Americas, where different strains of HIV are circulating.
Johnson & Johnson, based in New Brunswick and New Jersey, also makes one of three vaccines approved by U.S. regulators for the prevention of COVID-19. J&J is also developing vaccines against sepsis and respiratory syncytial virus.
.
|
Sources 2/ https://www.marketwatch.com/story/j-js-potential-hiv-vaccine-falls-short-in-sub-saharan-africa-trial-01630425157 The mention sources can contact us to remove/changing this article |
[ad_2]